BPH

Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types

Retrieved on: 
Tuesday, April 2, 2024
Urology, TFX, Development, Anatomy, ATC, Patient, Research and development, BPH, FDA, Physician, Medical imaging

The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significant advancement in BPH care.

Key Points: 
  • The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significant advancement in BPH care.
  • Bringing the enhanced tissue control capabilities onto the innovative and proven UroLift™ 2 platform allows me to deliver unparalleled precision to treat a broad spectrum of patients and anatomies.
  • It has transformed my approach to BPH care,” said Dr. Adam Craig Thomas of Parkview Physicians Group Urology in Fort Wayne, Indiana.
  • It ensures I’m always equipped to treat a broad range of patients with unique prostate types and anatomies.”
    To learn more about UroLift™ 2 ATC, visit UroLift.com .

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Retrieved on: 
Friday, March 22, 2024
Software, Radiology, Surgery, General Health, Health, Artificial Intelligence, Medical Devices, Technology, PAE, Interventional radiology, Automation, 2D, ASSIST, Vascular disease, Drainage, Prostatic artery embolization, Allia, OEC, Patient, Artificial intelligence, Society of Interventional Radiology, 3D, Prostate, AI, Quality of life, Artery, Woman, Workflow, GE HealthCare, 3D CT, Embo, E10, Injection, Therapy, BPH, SIR, Medical imaging

GE HealthCare (Nasdaq: GEHC) will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) will showcase its latest technologies in image guiding solutions, surgery, ultrasound and CT-navigation at the upcoming 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting taking place March 23-28 in Salt Lake City, UT.
  • The multi-modality showcase will feature innovations focused on precision care delivery for a wide range of vascular diseases and health conditions.
  • As GE HealthCare continues to advance the Allia IGS platform and interventional innovation, Embo ASSIST AI is the latest addition to the company's ASSIST imaging software.
  • “Interventional CT: CT guidance assisted by electromagnetic navigation for percutaneous interventions” with Dr. Francois Cornelis10 on Monday, March 25 from 2:30 - 3:00pm.

Laborie Medical Technologies Invests in iO Urology and the CarePath Uroflow Device

Retrieved on: 
Friday, March 29, 2024
Urology, Disease, Education, Patient, LUTS, Malignancy, BPH, FDA, Pharmaceutical industry

PORTSMOUTH, N.H., March 29, 2024 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced its investment in iO Urology, a venture-backed medical technology company that developed CarePath® an at-home, handheld uroflow device that is FDA-approved and has been utilized in multiple urology clinics in the U.S.

Key Points: 
  • PORTSMOUTH, N.H., March 29, 2024 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. (Laborie) announced its investment in iO Urology, a venture-backed medical technology company that developed CarePath® an at-home, handheld uroflow device that is FDA-approved and has been utilized in multiple urology clinics in the U.S.
    CarePath's simplistic model allows the device to be shipped directly to the patient's home and uses embedded cellular connectivity.
  • With CarePath, 91% of patients returned to the clinic to review the CarePath Uroflow report with their provider and consider surgical intervention.
  • "The team at iO Urology developed a state-of-the-art device with a dynamic patient ecosystem that empowers patient engagement as a superior standard of care.
  • "We're eager to collaborate with Laborie, pioneers in diagnostic and therapeutic urologic healthcare," said iO Urology Co-Founder and CEO Britton Garrett.

Journal of Pharmaceutical Analysis (JPA) Studies Find Promising Drug Candidates

Retrieved on: 
Friday, March 29, 2024
Hydralazine, Issue 1, DHT, Pigment, UBA52, Neuroregeneration, Prevalence, Apoptosis, PNI, Serum, Homeostasis, Patient, Ferroptosis, JPA, Neuron, HYD, Metformin, Type, Nerve, BPH, Hypopigmentation, EB, Depigmentation, Met, Oxidative stress, Iron, Pharmaceutical industry

XI'AN, China, March 29, 2024 /PRNewswire/ -- Understanding the underlying mechanisms of normal and pathological cellular processes is essential for developing new drugs. Fortunately, modern techniques and experimental methods have greatly accelerated progress. The latest issue of JPA features three articles in which candidate compounds for treating complex disorders were successfully identified, alongside their detailed mechanisms of action.

Key Points: 
  • The first study investigated the use of metformin (Met), a drug used to manage type II diabetes, for treating benign prostate hyperplasia (BPH).
  • The article was published in Volume 14, Issue 1 of the journal in January 2024 .
  • Using the Drug Signatures Database, they identified hydralazine (HYD), a potent arterial vasodilator, as a potential UBA52 disruptor.
  • Further studies will hopefully clarify the intricate connections among cellular processes, diseases, and potential drugs, paving the way for precise and efficient therapies.

Olympus Announces iTind™ Treatment Milestone with Availability Through Major GPOs

Retrieved on: 
Thursday, March 28, 2024
Urination, Risk, Prostate, Nursing, BPH, Hospital, Improper integral, GPO

CENTER VALLEY, Pa., March 28, 2024 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today a milestone for its iTind™ device with its availability and greater patient access through the largest healthcare group purchasing organization (GPO) contracts in the United States.

Key Points: 
  • The iTind procedure is a minimally invasive procedure for the treatment of benign prostatic hyperplasia (BPH) or enlarged prostate.
  • The Healthcare Supply Chain Association estimates nearly all hospitals and a majority of non-acute care centers in America belong to at least one GPO.1
    "The availability of the iTind device through major GPO contracts marks an important milestone for Olympus," said Jay Sullivan, Group Vice President, Enterprise Solutions, Medical Systems Group, Olympus.
  • BPH is a common health problem for men over 50 as the risk increases with age.
  • Symptoms of BPH include frequent urination with a sense of urgency and a weak urinary stream and excessive urination at night.2

Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024
International, Doctor of Philosophy, PIN, Prostate cancer, Research, Intelligence, Telephone, Marketing, Webcast, TSX, Food, GG5, Sale, Annual report, Travel, BPH, S&D, Consultant, Prostate, Level 1, Food and Drug Administration, Patient, News, Clinical trial, Insurance, G&A, Siemens Healthineers, International Financial Reporting Standards, MRI, Software, GG1, Category 1, Cryptocurrency

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Fourth quarter 2023 revenue increased 60% from approximately $1.3 million in the same three-month period a year ago.
  • G&A expenses for the 2023 fourth quarter increased by 41% to approximately $3.0 million, compared with approximately $2.1 million in the same period in 2022.
  • Fourth quarter 2023 S&D expenses increased by 74% to approximately $2.9 million, compared with $1.7 million in the fourth quarter of 2022.

PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 27, 2024
International, SAN, Total, Research, Investment, Marketing, Growth, BPH, GAAP, Urology, Health, Interest, Video game

Gross margin for the fourth quarter 2023 was 49% compared to 45% in the prior year period.

Key Points: 
  • Gross margin for the fourth quarter 2023 was 49% compared to 45% in the prior year period.
  • Operating expenses in the fourth quarter of 2023 were $50.8 million, compared with $35.7 million in the prior year period.
  • Net loss was $27.5 million for the fourth quarter of 2023, compared to a loss of $28.2 million in the prior year period.
  • Adjusted EBITDA was a loss of $23.3 million for the fourth quarter of 2023, compared to a loss of $21.7 million in the prior year period.

Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

Retrieved on: 
Tuesday, February 27, 2024
Interventional oncology, University College London, Division, FRCS, Magnetic resonance, Prostate cancer, MD, Temperature, UCL, TSX, Surgeon, BPH, Prostate, Patient, Helium, Diagnosis, Deep learning, Claustrophobia, Workflow, Siemens Healthineers, MRI, Cancer, Partnership, Medical imaging

TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.

Key Points: 
  • TULSA is a “one-and-done” procedure, performed in a single session that takes a few hours, and no hospital stay is required.
  • At less than 7,700 Lbs and 80 inches high, MAGNETOM Free.Max is the most lightweight, compact whole-body scanner ever offered by Siemens Healthineers.
  • I commend the teams at Siemens Healthineers and Profound as they work to achieve the convergence of their respective diagnostic and interventional MR technologies.
  • We look forward to collaborating with Profound to help expand access to TULSA as well.

Associated Medical Professionals of NY Revolutionizes Men's Health Care with Groundbreaking New IR Center and BPH Treatment Initiative

Retrieved on: 
Tuesday, March 5, 2024
Health Technology, Other Health, Radiology, Pharmaceutical, Surgery, Practice Management, Oncology, Managed Care, General Health, Seniors, Hospitals, Men, Biotechnology, Consumer, Health, Hospital, Urology, Interventional radiology, Physician, Prostate, Clinical research, Risk, BPH, PAE, Patient, A.M.P, Corporation, Prostatic artery embolization, Medical imaging

is an affiliate of U.S. Urology Partners , one of the nation’s largest independent providers of urology and related specialty services.

Key Points: 
  • is an affiliate of U.S. Urology Partners , one of the nation’s largest independent providers of urology and related specialty services.
  • The new initiative will include a collaboration between Associated Medical Professionals of NY and Prostate Centers USA®, furthering A.M.P.
  • Dr. Christopher M. Pieczonka, Chief Executive Officer of Associated Medical Professionals of NY and Corporate Director of Clinical Research of U.S. Urology Partners , stated, “ A.M.P.
  • has long been committed to being the leader in men’s health care , empowering men to live their lives to the fullest.

InventHelp Inventor Develops Means to Create a Urine Passage for Enlarged Prostate Tissue (LBT-8305)

Retrieved on: 
Monday, February 12, 2024
DEPT, Urination, Incidence, Multimedia, Suite, Quality of life, Pain, Prostate, Hyperplasia, Sale, FLO, BPH, Urine

My design would eliminate the need for a man with an enlarged prostate to continually wake throughout the night to urinate."

Key Points: 
  • My design would eliminate the need for a man with an enlarged prostate to continually wake throughout the night to urinate."
  • The invention provides an effective way to treat prostate gland enlargement or benign prostatic hyperplasia.
  • In doing so, it reduces the incidence of urine leakage, frequent urination during the night, and urgency or inability to urinate.
  • 22-LBT-8305, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.